A detailed history of Orchard Capital Managment, LLC transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Orchard Capital Managment, LLC holds 1,980,198 shares of HRTX stock, worth $2.22 Million. This represents 2.09% of its overall portfolio holdings.

Number of Shares
1,980,198
Previous 2,243,426 11.73%
Holding current value
$2.22 Million
Previous $7.85 Million 49.82%
% of portfolio
2.09%
Previous 2.62%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$1.73 - $3.67 $455,384 - $966,046
-263,228 Reduced 11.73%
1,980,198 $3.94 Million
Q2 2024

Aug 13, 2024

SELL
$2.32 - $3.86 $66,020 - $109,844
-28,457 Reduced 1.25%
2,243,426 $7.85 Million
Q1 2024

May 14, 2024

BUY
$1.71 - $3.06 $48,661 - $87,078
28,457 Added 1.27%
2,271,883 $6.29 Million
Q4 2023

Feb 14, 2024

BUY
$0.54 - $1.82 $54,325 - $183,097
100,603 Added 4.69%
2,243,426 $3.81 Million
Q3 2023

Nov 14, 2023

BUY
$0.97 - $1.8 $729,190 - $1.35 Million
751,743 Added 54.04%
2,142,823 $2.21 Million
Q2 2023

Sep 01, 2023

SELL
$1.11 - $2.88 $1.39 Million - $3.6 Million
-1,251,123 Reduced 47.35%
1,391,080 $1.61 Million
Q2 2023

Aug 14, 2023

BUY
$1.11 - $2.88 $1.39 Million - $3.6 Million
1,251,123 Added 89.94%
2,642,203 $3.06 Million
Q3 2022

Nov 15, 2022

BUY
$2.66 - $5.37 $971,048 - $1.96 Million
365,056 Added 35.58%
1,391,080 $5.87 Million
Q2 2022

Aug 15, 2022

BUY
$2.3 - $6.29 $135,930 - $371,739
59,100 Added 6.11%
1,026,024 $2.85 Million
Q1 2022

May 16, 2022

BUY
$4.63 - $9.94 $2.78 Million - $5.97 Million
600,920 Added 164.18%
966,924 $5.53 Million
Q4 2021

Feb 15, 2022

BUY
$8.35 - $12.6 $59,285 - $89,460
7,100 Added 1.98%
366,004 $3.34 Million
Q2 2021

Aug 17, 2021

BUY
$13.27 - $18.48 $4.76 Million - $6.63 Million
358,904 New
358,904 $5.57 Million

Others Institutions Holding HRTX

About HERON THERAPEUTICS, INC.


  • Ticker HRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 118,774,000
  • Market Cap $133M
  • Description
  • Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...
More about HRTX
Track This Portfolio

Track Orchard Capital Managment, LLC Portfolio

Follow Orchard Capital Managment, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Orchard Capital Managment, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orchard Capital Managment, LLC with notifications on news.